We conducted a prospective pilot study to assess the feasibility and safety of high-dose busulfan/melphalan as conditioning therapy prior to autologous PBPC transplantation in pediatric patients with high-risk solid tumors. From January 1995 to January 1999, 30 patients aged 2-21 years (median 8) were entered into the study. There were 14 females and 16 males. Diagnoses included neuroblastoma in 10 patients; Ewing's sarcoma and peripheral neuroectodermal tumor (PNET) in 15 patients and rhabdomyosarcoma in five patients. Treatment consisted of busulfan 16 mg/kg, orally over 4 days (from days ؊5 to ؊2) in 6 hourly divided doses, and melphalan at a dose of 140 mg/m 2 given by intravenous infusion over 5 min on day ؊1. G-CSF mobilized PBPC were used as autologous stemcell rescue. One patient developed a single generalized convulsion during busulfan therapy. The most relevant non-hematologic toxicity was gastrointestinal, manifesting as grade 2-3 mucositis and diarrhea in 12 patients. Two patients died of procedure-related complications, one from veno-occlusive disease of liver and multiorgan failure and the other from adult respiratory distress syndrome. Probability of treatment-related mortality was 6.6 ؎ 4.5%. With a median follow-up of 18 months (range, 1-48), 19 patients are alive and disease-free, the actuarial EFS at 4 years being 55 ؎ 12% for the whole group. We conclude that high-dose busulfan/melphalan for autologous transplantation in children with solid tumors is feasible even in small patients. It is well-tolerated, with an acceptable transplant-related mortality and has proven antitumor activity. Keywords: busulfan/melphalan; solid tumors; PBPC transplantation; children Children with advanced or recurrent solid tumor have a poor prognosis. High-dose chemotherapy followed by autologous hematopoietic cell rescue has improved this situation.
introduced as consolidation for pediatric patients with highrisk relapsed solid tumors. 2 However, the best conditioning regimen has not yet been established. High-dose chemotherapy regimens should consist of one or several agents that have dose-response-related anti-cancer activity and do not have overlapping extra-hematological toxicities. Busulfan is currently used at high doses in preparative regimens for hematopoietic transplantation. Liver toxicity is doselimiting for busulfan as a single agent. 3 Melphalan has demonstrated activity in high doses for relapsed or refractory solid tumors in children and its primary toxicity is myelosuppression. [4] [5] A preparative regimen based on highdose busulphan and melphalan has been used for transplantation in patients with hematological malignancies in adults with low toxicity. [6] [7] [8] Based on previous experience, we conducted a pilot study to assess the feasibility and safety of high-dose busulfan and melphalan as conditioning therapy followed by mobilized peripheral blood progenitor cell (PBPC) support in pediatric patients with high-risk solid tumors.
Patients and methods

Patients
From January 1995 to January 1999, 30 patients were entered into the study. Eligibility criteria included: age up to 21 years, Lansky's performace status Ͼ70%, left ventricular ejection fraction Ͼ50%, and normal liver and kidney function. There were 14 females and 16 males with a median age of 8 years (range, 2-21). Patient characteristics are given in Table 1 . Written informed consent regarding the use of conditioning therapy and PBPC mobilization and collection, was obtained from parents or guardians in all cases.
PBPC mobilization and collection
PBPC were mobilised with G-CSF (filgrastim) alone, 12 g/kg/day s.c. (neupogen; Amgen, Thousand Oaks, CA, USA) for 4 days before starting the collection. PBPC collections were carried out using a COBE Spectra cell separator (COBE, Denver, CO, USA) through a double lumen central venous catheter, as previously published. 9, 10 
Conditioning regimen and supportive therapy
All patients received busulfan 16 mg/kg, orally over 4 days (from days Ϫ5 to Ϫ2) in 6 hourly divided doses, and melphalan at a dose of 140 mg/m 2 , by intravenous infusion over 5 min on day Ϫ1. Intravenous clonazepam at a dose of 0.1 mg/kg/day was given from the first day of busulfan to the infusion day in order to avoid busulfan-related neurological toxicity. Transplants were carried out in reversebarrier isolation rooms. Cryopreserved PBPC were infused after rapid thawing at 37°C on day 0.
Diphenhydramine (1 mg/kg) and methylprednisolone (2 mg/kg) were given to prevent dimethylsulfoxide toxicity. All patients received G-CSF (10 g/kg/day) starting on day ϩ1 until neutrophil engraftment. Empiric i.v. antibiotic treatment was initiated as soon as fever occurred. Leukocyte-depleted, phenotyped and irradiated blood products were used to maintain a hemoglobin level Ͼ8 g/l and platelet count Ͼ10 ϫ 10 9 /l. Non-hematological toxicity was graded according to Bearman's criteria. 11 
Statistical analysis
Engraftment kinetics and survival analysis was carried out using the Kaplan-Meier method. Event-free survival (EFS) was defined as time from day 0 until disease progression or relapse, or any cause of death. The median follow-up time since transplantation is 18 months (range, 1-48).
Results
Hematopoietic recovery
The median number of infused CD34 ϩ cells was 3.1 ϫ 10 6 /kg (range 0.17-12.9). All patients experienced severe myelosuppression. Hematopoietic recovery was evaluated in terms of median number of days to achieve an absolute neutrophil count of Ͼ0.5 ϫ 10 9 /l and an unsupported platelet count of Ͼ20 ϫ 10 9 /l. These values were: 9 days (range, 7-16) and 12 days (range, 8-91), respectively. Ninety-five percent of patients achieved neutrophil and platelet engraftment on day 11 and 33, respectively. The median number of febrile days was 3 (range, 1-15), with a median number of days on i.v. antibiotics of 10 (range, 2-33). Patients were hospitalized 18 days (range, 10-38) from infusion day until discharge.
Non-hematological toxicity
All patients experienced moderate nausea and vomiting during conditioning. One patient had a single grand mal convulsion. During the period of myelosuppression, the most relevant non-hematologic toxicity was to the gastrointestinal tract manifesting as grade 2-3 mucositis and diarrhea in 12 patients who needed parenteral narcotics to treat for pain for a median of 6 days (range, 2-16). All patients received total parenteral nutrition (median time 18 days, range, 7-41). Grade 1 liver toxicity was observed in three patients. Two patients died of procedure-related complications within the first 100 days, one from veno-occlusive disease of liver (VOD) and multiorgan failure and the other one from adult respiratory distress syndrome. Probability of treatment-related mortality was 6.6 Ϯ 4.5%. No other relevant toxicities were observed.
Event-free survival (EFS)
At the time of writing (March 1999), 19 patients are alive and disease-free, one patient is alive with relapsed disease and 10 patients died. Causes of death were as follows: treatment-related, two patients, relapsed and/or progressive disease eight patients, with a median time to relapse of 2 months (range, 1-32) after transplantation.
Actuarial EFS is 55 Ϯ 12% at 4 years for whole group. For Ewing's sarcoma/PNET patients, actuarial EFS is 64 Ϯ 16.5% at 4 years with a median observation time of 12 months (range, 1-46) and for neuroblastoma patients this probability is 35 Ϯ 16% with a median follow-up time of 5 months (range, 1-48).
Discussion
High-dose chemotherapy and autologous stem cell rescue is being increasingly used for treatment of high-risk solid tumors in pediatric patients. The EBMT data suggest that megatherapy has a positive impact in some tumors such as Ewing's sarcoma, PNET, rhabdomyosarcoma and neuroblastoma.
1 For Ewing's sarcoma, more than 20 different regimens have been used. 2 Although there is no advantage of one particular regimen over another, there is a trend indicating that chemotherapy-based regimens are better in terms of EFS. 2 However, the best conditioning regimen for solid tumors has not yet been established. The ideal conditioning regimen should be easy to administer, well-tolerated, active against the majority of tumors and inexpensive.
High-dose busulfan and melphalan as conditioning therapy has been used for hematologic and non-hematologic malignancies in both adults and children. [6] [7] [8] 12 In the present study, busulfan was easily administered even to small patients. The major side-effect during conditioning was moderate nausea and vomiting that was well controlled with antiemetics. We used clonazepam to prevent neurological problems based on the fact that it has been shown that phenytoin may enhance busulphan metabolism. 13 Only one patient had a single grand mal convulsion attributable to busulfan treatment. Following PBPC infusion all patients experienced severe myelosuppression. Hematopoietic recovery was rapid as anticipated from our previous experience. 14, 15 During the neutropenic period the most significant toxicities involved the gastrointestinal tract, manifesting as grade 2-3 mucositis and diarrhea in 40% of patients. All of them needed i.v. morphine for pain relief. Transplantrelated mortality was similar to that previously published by others. 12 As indicated by others, 12 one possible explanation for the low conditioning-related toxicity in our series, especially VOD, could be that busulfan was given based on body weight alone. It leads to a lower area under the concentration curve (AUC) than when the busulfan dose is based on surface area. [16] [17] [18] More consistent AUC levels may lead to increased toxicity.
In terms of EFS our results are similar to those published by others 2, 12, [19] [20] [21] using either the same conditioning regimen or other high-dose regimens for solid tumor in children.
In conclusion, our results suggest that high-dose busulfan/melphalan and autologous transplantation in children with solid tumors is feasible to administer even to small patients, that it is well-tolerated with an acceptable transplant-related mortality and that it has proven antitumor activity.
